Literature DB >> 18853311

Anti-epidermal growth factor receptor strategies for advanced breast cancer.

Susana M Campos1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18853311     DOI: 10.1080/07357900801971040

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  5 in total

1.  Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.

Authors:  Taichang Yuan; Yongping Wang; Zhizhuang J Zhao; Haihua Gu
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

2.  Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.

Authors:  Susana M Campos; Suzanne T Berlin; Leroy M Parker; Wendy Y Chen; Craig A Bunnell; Tina Atkinson; Julie Lee; Ursula Matulonis; Michelle S Hirsch; Lyndsay Harris; Carolyn N Krasner
Journal:  Int J Clin Oncol       Date:  2010-04-20       Impact factor: 3.402

3.  Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.

Authors:  Ying-Xue Wang; Jin-Xiang Gao; Xiu-Yun Wang; Li Zhang; Chang-Mei Liu
Journal:  Tumour Biol       Date:  2012-01-18

Review 4.  ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.

Authors:  Jin-Qiang Chen; Jose Russo
Journal:  Biochim Biophys Acta       Date:  2009-06-13

5.  GPR54 (KISS1R) transactivates EGFR to promote breast cancer cell invasiveness.

Authors:  Mateusz Zajac; Jeffrey Law; Dragana Donna Cvetkovic; Macarena Pampillo; Lindsay McColl; Cynthia Pape; Gianni M Di Guglielmo; Lynne M Postovit; Andy V Babwah; Moshmi Bhattacharya
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.